ACTRN12611000488909
Recruiting
Not Applicable
People with Type 2 diabetes currently treated with thiazolidinediones supplemented with Vitamin C and the combined effect on adiponectin as a therapeutic for metabolic disease.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Type 2 diabetes
- Sponsor
- Princess Alexandra Hospital
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female or male participants between the ages of 18 and 70 with non insulin dependent type 2 diabetes under TZD treatment (either rosiglitazone 4 – 8 mg or piogitazone greater than or equal 30 mg) with or without metformin.
- •HbA1C level 7 – 8\.5 %.
- •Participant on stable diabetic therapy for three months prior to the intervention.
Exclusion Criteria
- •HbA1C level greater than 8\.5 %
- •Participants must have a stable body weight (\< 5% selfreported weight loss/gain) within last 3 months prior to enrolment.
- •Participants taking iron supplements.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Randomised efficacy and safety clinical trial of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass polleSeasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposureMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2019-001517-16-CZAllergy Therapeutics (UK) Ltd.1,342
Active, not recruiting
Phase 1
Randomised efficacy and safety clinical trial of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass polleSeasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposureMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2019-001517-16-ATAllergy Therapeutics (UK) Ltd.1,342
Completed
Not Applicable
A randomised, double-blind, placebo-controlled clinical trial of a Compound Herbal Preparation (CHP) in the treatment of children with Attention-Deficit Hyperactivity Disorder (ADHD)ISRCTN10628149Etz-HaChayim Clinic (Israel)120
Active, not recruiting
Phase 1
Randomised efficacy and safety clinical trial of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass polleSeasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposureMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2019-001517-16-HUAllergy Therapeutics (UK) Ltd.1,204
Not yet recruiting
Not Applicable
A randomised, double-blind, placebo-controlled clinical trial to determine the effects of MaZiRenWan granules on functional constipation and constipation-predominant irritable bowel syndromeITMCTR2100004417Hong Kong Baptist University